CCL20

Across TCGA pan-cancer cohorts, CCL20 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of CCL20’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where CCL20 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types CCL20 is over-expressed in tumor.

LSCC, LUAD, and COAD are the cancer types where CCL20 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CCL20 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+1.269	<.001	8	view →
LUAD	Male	All	+0.719	<.001	4	view →
COAD	All	All	+0.568	.006	3	view →
CCRCC	All	All	+0.512	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

CCL20–LSCC

Open the LSCC breakdown →